{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:19:28Z","timestamp":1764181168051,"version":"3.46.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04820-6","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T14:15:10Z","timestamp":1763993710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2623-5032","authenticated-orcid":false,"given":"Veerendra Kumar","family":"Panuganti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrasekhar Varma","family":"Alluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkata Ramalingayya","family":"Grandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javeed","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanyasirao","family":"K. S. S. V. V.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamatha Reddy","family":"Dundigalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavan Kumar","family":"Madala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"23","key":"4820_CR1","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482\u201394. https:\/\/doi.org\/10.1056\/NEJMra0706547","journal-title":"N Engl J Med"},{"issue":"8","key":"4820_CR2","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/bjc.1997.507","volume":"76","author":"M de Boer-Dennert","year":"1997","unstructured":"de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76(8):1055\u20131061. https:\/\/doi.org\/10.1038\/bjc.1997.507PMID: 9376266; PMCID: PMC2228081","journal-title":"Br J Cancer"},{"issue":"5","key":"4820_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497\u2013503. https:\/\/doi.org\/10.1007\/s00520-006-0173-z","journal-title":"Support Care Cancer"},{"issue":"6","key":"4820_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00520-010-0915-9","volume":"19","author":"A Haiderali","year":"2011","unstructured":"Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J (2011) Impact on daily functioning and indirect\/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer 19(6):843\u2013851. https:\/\/doi.org\/10.1007\/s00520-010-0915-9. (Epub 2010 Jun 9. PMID: 20532923)","journal-title":"Support Care Cancer"},{"issue":"7","key":"4820_CR5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","volume":"25","author":"RJ Gralla","year":"2014","unstructured":"Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25(7):1333\u20131339. https:\/\/doi.org\/10.1093\/annonc\/mdu096","journal-title":"Ann Oncol"},{"issue":"19","key":"4820_CR6","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2217\/fon-2017-0189","volume":"13","author":"G Kov\u00e1cs","year":"2017","unstructured":"Kov\u00e1cs G, Wachtel A, Basharova E, Spinelli T, Nicolas P, Kabickova E (2017) Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized phase III study. Future Oncol 13(19):1685\u20131698. https:\/\/doi.org\/10.2217\/fon-2017-0189. (Epub 2017 Jun 1. PMID: 28569078)","journal-title":"Future Oncol"},{"issue":"1","key":"4820_CR7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1186\/s12885-020-07259-5","volume":"20","author":"C Weinstein","year":"2020","unstructured":"Weinstein C, Jordan K, Green S, Khanani S, Beckford-Brathwaite E, Vallejos W, Pong A, Noga SJ, Rapoport BL (2020) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type. BMC Cancer 20(1):918. https:\/\/doi.org\/10.1186\/s12885-020-07259-5PMID: 32988373; PMCID: PMC7523353","journal-title":"BMC Cancer"},{"key":"4820_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2165\/00003495-199345060-00006","volume":"45","author":"A Markham","year":"1993","unstructured":"Markham A, Sorkin EM, Ondansetron (1993) Drugs 45:931\u2013952. https:\/\/doi.org\/10.2165\/00003495-199345060-00006","journal-title":"Drugs"},{"doi-asserted-by":"publisher","unstructured":"Baba Y, Baba H, Yamamoto S, Shimada H, Shibata T, Miyazaki T, Yoshikawa T, Nakajima Y, Tsuji Y, Shimokawa M, Kitagawa Y, Aiba K (2017) Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan. Dis Esophagus. ;30(2):1\u20137. https:\/\/doi.org\/10.1111\/dote.12482. PMID: 27001532","key":"4820_CR9","DOI":"10.1111\/dote.12482"},{"key":"4820_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/TCRM.S81126","volume":"12","author":"PK Janicki","year":"2016","unstructured":"Janicki PK (2016) Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combination. Ther Clin Risk Manag 12:693\u2013699. https:\/\/doi.org\/10.2147\/TCRM.S81126","journal-title":"Ther Clin Risk Manag"},{"key":"4820_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00019","volume":"8","author":"BL Rapoport","year":"2017","unstructured":"Rapoport BL (2017) Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management. Front Pharmacol 8:19. https:\/\/doi.org\/10.3389\/fphar.2017.00019","journal-title":"Front Pharmacol"},{"issue":"2","key":"4820_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1213\/ANE.0000000000004833","volume":"131","author":"TJ Gan","year":"2020","unstructured":"Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, Jin Z, Kovac AL, Meyer TA, Urman RD, Apfel CC, Ayad S, Beagley L, Candiotti K, Englesakis M, Hedrick TL, Kranke P, Lee S, Lipman D, Minkowitz HS, Morton J, Philip BK (2020) Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 131(2):411\u2013448. https:\/\/doi.org\/10.1213\/ANE.0000000000004833","journal-title":"Anesth Analg"},{"issue":"4","key":"4820_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JCO.2015.64.3635","volume":"34","author":"PJ Hesketh","year":"2016","unstructured":"Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, Danso MA, Jordan K, Somerfield MR, Kris MG, American Society of Clinical Oncology (2016) Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 34(4):381\u20136. https:\/\/doi.org\/10.1200\/JCO.2015.64.3635","journal-title":"J Clin Oncol"},{"issue":"31","key":"4820_CR14","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189\u201398. https:\/\/doi.org\/10.1200\/JCO.2010.34.4614","journal-title":"J Clin Oncol"},{"issue":"4","key":"4820_CR15","first-page":"232","volume":"5","author":"KV Rao","year":"2012","unstructured":"Rao KV, Faso A (2012) Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits 5(4):232\u2013240 PMID: 24991322; PMCID: PMC4046471","journal-title":"Am Health Drug Benefits"},{"issue":"6","key":"4820_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1188\/07.CJON.809-813","volume":"11","author":"M Vrabel","year":"2007","unstructured":"Vrabel M (2007) Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials. Clin J Oncol Nurs 11(6):809\u201313. https:\/\/doi.org\/10.1188\/07.CJON.809-813","journal-title":"Clin J Oncol Nurs"},{"unstructured":"Granisetron extended release (ER) injection, Prescribing Information, Sustol\u00ae FDA Label Revised on 08\/2016","key":"4820_CR17"},{"key":"4820_CR18","first-page":"83","volume":"7","author":"N Gabrail","year":"2015","unstructured":"Gabrail N, Yanagihara R, Spaczy\u0144ski M, Cooper W, O\u2019Boyle E, Smith C, Boccia R (2015) Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two phase II trials. Cancer Manag Res 7:83\u201392 PMID: 25834466; PMCID: PMC4370683","journal-title":"Cancer Manag Res"},{"key":"4820_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12618","author":"D Lorusso","year":"2017","unstructured":"Lorusso D, Bria E, Costantini A, Di Maio M, Rosti G, Mancuso A (2017) Patients\u2019 perception of chemotherapy side effects: expectations, doctor-patient communication and impact on quality of life - an Italian survey. Eur J Cancer Care (Engl). https:\/\/doi.org\/10.1111\/ecc.12618","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"4","key":"4820_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1127","volume":"1","author":"M Aapro","year":"2018","unstructured":"Aapro M, Ruffo P, Panteri R, Costa S, Piovesana V (2018) Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. Cancer Rep (Hoboken) 1(4):e1127. https:\/\/doi.org\/10.1002\/cnr2.1127","journal-title":"Cancer Rep (Hoboken)"},{"key":"4820_CR21","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.2147\/DDDT.S86415","volume":"9","author":"Y Zhu","year":"2015","unstructured":"Zhu Y, Zhang Q, Zou J, Wan M, Zhao Z, Zhu J (2015) Pharmacokinetics and bioavailability study of two Ondansetron oral soluble film formulations in fasting healthy male Chinese volunteers. Drug Des Devel Ther 9:4621\u20134629. https:\/\/doi.org\/10.2147\/DDDT.S86415","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"4820_CR22","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","volume":"17","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdl137","journal-title":"Ann Oncol"},{"issue":"6","key":"4820_CR23","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, Jordan K, Young A, Aapro M (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28(6):1260\u20131267. https:\/\/doi.org\/10.1093\/annonc\/mdx100","journal-title":"Ann Oncol"},{"key":"4820_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278","volume":"26","author":"K Gupta","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP (2021) Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun 26:100278. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100278","journal-title":"Cancer Treat Res Commun"},{"issue":"9","key":"4820_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00520-006-0186-7","volume":"15","author":"K Jordan","year":"2007","unstructured":"Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, Schmoll HJ (2007) A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 15(9):1023\u201333. https:\/\/doi.org\/10.1007\/s00520-006-0186-7","journal-title":"Support Care Cancer"},{"doi-asserted-by":"publisher","unstructured":"Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. ;100(10):2261-8. https:\/\/doi.org\/10.1002\/cncr.20230. PMID: 15139073","key":"4820_CR26","DOI":"10.1002\/cncr.20230"},{"issue":"1","key":"4820_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00520-014-2373-2","volume":"23","author":"RK Hsieh","year":"2015","unstructured":"Hsieh RK, Chan A, Kim HK, Yu S, Kim JG, Lee MA, Dal\u00e9n J, Jung H, Liu YP, Burke TA, Keefe DM (2015) Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer 23(1):263\u2013272. https:\/\/doi.org\/10.1007\/s00520-014-2373-2","journal-title":"Support Care Cancer"},{"issue":"12","key":"4820_CR28","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.2217\/fon-2016-0070","volume":"12","author":"ID Schnadig","year":"2016","unstructured":"Schnadig ID, Agajanian R, Dakhil C, Gabrail NY, Smith RE Jr, Taylor C, Wilks ST, Schwartzberg LS, Cooper W, Mosier MC, Payne JY, Klepper MJ, Vacirca JL (2016) APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. Future Oncol 12(12):1469\u20131481. https:\/\/doi.org\/10.2217\/fon-2016-0070Epub 2016 Mar 21. PMID: 26997579","journal-title":"Future Oncol"},{"unstructured":"Palonosetron IV injection Prescribing Information, Aloxi\u00ae FDA Label Revised on 05\/2014","key":"4820_CR29"},{"unstructured":"Ondansetron Prescribing information, Zofran\u00ae, FDA Label","key":"4820_CR30"},{"doi-asserted-by":"publisher","unstructured":"Wilde MI, Markham A, Ondansetron (1996) A review of its pharmacology and preliminary clinical findings in novel applications. Drugs. ;52(5):773\u2009\u2013\u200994. https:\/\/doi.org\/10.2165\/00003495-199652050-00010. PMID: 9118822","key":"4820_CR31","DOI":"10.2165\/00003495-199652050-00010"},{"issue":"5","key":"4820_CR32","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1034\/j.1600-0773.2001.d01-111.x","volume":"88","author":"P Behnam-Motlagh","year":"2001","unstructured":"Behnam-Motlagh P, Sandstr\u00f6m PE, Henriksson R, Grankvist K (2001) Diverging effects of 5-HT3 receptor antagonists ondansetron and granisetron on estramustine-inhibited cellular potassium transport. Pharmacol Toxicol 88(5):244\u20139. https:\/\/doi.org\/10.1034\/j.1600-0773.2001.d01-111.x","journal-title":"Pharmacol Toxicol"},{"doi-asserted-by":"publisher","unstructured":"Hakamifard A, Aria A,Momenzadeh M. Severe Ondansetron-associated Hypokalemia in a Patient Diagnosed withAspiration Pneumonia. J Res Pharm Pract 2022 Dec 14;11(2):87-90. https:\/\/doi.org\/10.4103\/jrpp.jrpp_13_22","key":"4820_CR33","DOI":"10.4103\/jrpp.jrpp_13_22"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04820-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04820-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04820-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:16:00Z","timestamp":1764180960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04820-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4820"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04820-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VKP has a patent, Ondansetron Extendable Release Injectable Suspension and Methods of Use pending to Shilpa Medicare Limited. All the authors, VKP, CVA, VRG, JM, KSSVVS, MRD and PKM of this manuscript are the current employees of Shilpa Medicare Limited and declares no other conflict of interest in view of publication of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}